

CHARKOT, Julia, BIEŃKOWSKI, Wojciech and JASZCZUK, Irmína. The Role of *Lactobacillus reuteri* DSM 17938 in Athletic Performance and Recovery. Quality in Sport. 2025;43:61342. eISSN 2450-3118.

<https://doi.org/10.12775/QS.2025.43.61342>

<https://apcz.umk.pl/QS/article/view/61342>

The journal has been awarded 20 points in the parametric evaluation by the Ministry of Higher Education and Science of Poland. This is according to the Annex to the announcement of the Minister of Higher Education and Science dated 05.01.2024, No. 32553. The journal has a Unique Identifier: 201398. Scientific disciplines assigned: Economics and Finance (Field of Social Sciences); Management and Quality Sciences (Field of Social Sciences).

Punkty Ministerialne z 2019 - aktualny rok 20 punktów. Załącznik do komunikatu Ministra Szkolnictwa Wyższego i Nauki z dnia 05.01.2024 Lp. 32553. Posiada Unikatowy Identyfikator Czasopisma: 201398. Przypisane dyscypliny naukowe: Ekonomia i finanse (Dziedzina nauk społecznych); Nauki o zarządzaniu i jakości (Dziedzina nauk społecznych). © The Authors 2025.

This article is published with open access under the License Open Journal Systems of Nicolaus Copernicus University in Toruń, Poland. Open Access: This article is distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non-commercial Share Alike License (<http://creativecommons.org/licenses/by-nc-sa/4.0/>), which permits unrestricted, non-commercial use, distribution, and reproduction in any medium, provided the work is properly cited.

The authors declare that there is no conflict of interest regarding the publication of this paper.

Received: 30.06.2025. Revised: 11.07.2025. Accepted: 11.07.2025. Published: 14.07.2025.

The Role of *Lactobacillus reuteri* DSM 17938 in Athletic Performance and Recovery

Authors:

Julia Charkot

Medical University of Warsaw

<https://orcid.org/0009-0000-1224-3251>

Wojciech Bieńkowski

Szpital Grochowski im. dr med. Rafała Masztaka

<https://orcid.org/0009-0005-1776-8862>

Irmína Jaszczyk

Medical University of Warsaw

<https://orcid.org/0009-0001-7504-832X>

Abstract

Introduction and purpose: The gut microbiota plays a vital role in modulating health, immunity, and recovery, all of which are crucial for athletes. *Limosilactobacillus reuteri* DSM 17938 is a well-documented probiotic strain with anti-inflammatory, immunomodulatory, and gastrointestinal benefits. This review explores its potential application in supporting athletic performance and post-exercise recovery.

Material and method: A narrative literature review was conducted using PubMed, Scopus, and Google Scholar databases. Articles published between 2000 and 2024 were included, with a focus on clinical and experimental studies evaluating the effects of *L. reuteri* DSM 17938 on gastrointestinal function, inflammation, immune response, and athletic outcomes.

Results: Evidence suggests that *L. reuteri* DSM 17938 contributes to gut barrier integrity, reduces exercise-related gastrointestinal discomfort, modulates inflammatory cytokines (e.g., IL-6, TNF- α), and supports immune function. While direct evidence linking this strain to improvements in performance metrics (e.g., endurance, VO₂max) is limited, its supportive role in recovery and resilience is promising.

Conclusions: *L. reuteri* DSM 17938 shows potential as a functional supplement for athletes, particularly in improving gut health, reducing inflammation, and enhancing immune defense. Further clinical research is needed to confirm its direct effects on athletic performance.

Keywords: *Lactobacillus reuteri* DSM 17938, probiotics, athletic performance, recovery, gut microbiota, inflammation, immunity.

Introduction

Gut microbiota significantly influences both overall health and athletic performance through its multifaceted roles in metabolism, immune function, and mental health. Studies have indicated that gut bacteria help regulate energy homeostasis and maintain gut barrier integrity, both vital for preventing metabolic disorders and fostering recovery in athletes [1–3]. A balanced gut microbiota can enhance nutrient absorption and support muscle recovery, thereby influencing athletic outcomes [3–5].

Moreover, the gut-brain axis suggests that microbiota can affect psychological well-being; specific strains, like *Lactobacillus rhamnosus*, help mitigate stress-related behaviors, enhancing mental resilience in athletes [6]. The production of metabolites such as short-chain fatty acids by gut microbiota also contributes to the anti-inflammatory responses necessary for exercise recovery [7,8]. Therefore, the maintenance of diverse and balanced gut microbiota should be a priority for athletes focusing on peak performance and overall health.

Lactobacillus reuteri DSM 17938 plays a notable role in sports science, particularly concerning gastrointestinal health and immune support. Research indicates that this specific strain may help reduce exercise-induced gastrointestinal distress, a common issue faced by athletes, thereby potentially contributing to improved performance and comfort during training and competitions [9,10]. Additionally, probiotics such as *L. reuteri* have been shown to positively affect gut barrier function, which is crucial for nutrient absorption and recovery in competitive sports settings [11,12].

Another vital aspect of *L. reuteri*'s relevance in sports is its potential to modulate immune responses. Regular supplementation with this strain may enhance the body's defenses against upper respiratory infections, which can hinder training continuity [13]. Furthermore, the gut-brain axis, influenced by gut microbiota, highlights the potential of probiotics in improving mental resilience, particularly for athletes during intense competitive phases [9,14]. Thus, integrating *L. reuteri* DSM 17938 into the diets of athletes may contribute to both physical performance and psychological well-being.

Aim

The aim of this study is to explore the potential benefits of *Limosilactobacillus reuteri* DSM 17938 in the context of athletic performance and recovery. Specifically, the review focuses on the strain's effects on gut health, immune function, and inflammation-factors that play a crucial role in supporting athletes' physical condition and resilience. The goal is to assess current scientific evidence and highlight whether this probiotic can serve as a supportive tool in sports nutrition and recovery strategies.

Materials and methods

This work is based on a narrative literature review aimed at summarizing current knowledge about the potential role of *Limosilactobacillus reuteri* DSM 17938 in athletic performance and recovery. Scientific publications were searched in databases such as PubMed, Scopus, and Google Scholar using keywords including *L. reuteri* DSM 17938, *probiotics in sports*, *gut microbiota*, and *immune response in athletes*. The selection included peer-reviewed articles and clinical studies published in English from 2000 to 2024, with a focus on the probiotic's effects on gastrointestinal health, immune modulation, inflammation, and exercise-related outcomes. Non-relevant articles or those not related to DSM 17938 were excluded. The gathered data were analyzed qualitatively and grouped thematically to provide a comprehensive overview of the topic.

Review and discussion

***Lactobacillus reuteri* DSM 17938: Biological Properties and Health Potential**

Limosilactobacillus reuteri DSM 17938 is distinguished from other probiotic strains largely due to its specific safety profile, enhanced colonization ability, and diverse therapeutic activities. Regarding safety, DSM 17938 is derived from *L. reuteri* ATCC 55730 and is notable for lacking plasmids associated with antibiotic resistance, making it a safer option for pediatric use, especially in vulnerable populations such as infants [15–19].

In terms of colonization, studies suggest that DSM 17938 exhibits a robust ability to establish itself within the human gut microbiota, achieving significant persistence compared to other strains [17,18]. Its colonization potential is complemented by evidence demonstrating its effectiveness in addressing various gastrointestinal disorders, particularly infantile colic and acute gastroenteritis, where it consistently reduces symptoms and enhances gut health [20–23]. Additionally, DSM 17938 demonstrates notable anti-inflammatory properties, potentially aiding in conditions like inflammatory bowel diseases and offering protection against pathogens through mechanisms like competitive exclusion [24–26]. This multifaceted functional capacity underscores its prominence among probiotic strains [27,28].

Limosilactobacillus reuteri DSM 17938 exhibits notable immunological, anti-inflammatory, and gastrointestinal effects, distinguishing it as a relevant probiotic strain. Immunologically, it enhances the gut-liver axis, influencing immune responses that mitigate inflammation and enhance gut barrier integrity [16,29]. Studies have shown that DSM 17938 can downregulate pro-inflammatory cytokines such as interleukin-8, indicating its anti-inflammatory capabilities [16,26,30]. Furthermore, this strain has been associated with an increase in regulatory T cell populations, which play a significant role in immunomodulation [31].

In terms of gastrointestinal effects, DSM 17938 has demonstrated efficacy in improving gut motility and reducing symptoms of functional gastrointestinal disorders, particularly in infants with colic and constipation [32,33]. Clinical evidence indicates that it shortens the duration of acute infectious diarrhea in children and enhances gastric emptying, supporting its role in gastrointestinal health [34,35]. Moreover, *L. reuteri* DSM 17938 is recognized for its ability to produce antimicrobial metabolites like reuterin, further contributing to gastrointestinal wellness by inhibiting pathogen growth [26,36].

Limosilactobacillus reuteri DSM 17938 has been extensively studied across diverse populations, including infants and children, demonstrating various beneficial outcomes. In pediatric populations, particularly infants, DSM 17938 has been shown to reduce the duration of acute infectious diarrhea, alleviate symptoms of colic, and improve gastrointestinal function, evidenced by several randomized controlled trials [21,37–39]. For example, one study indicated that administration of DSM 17938 in infants led to a significant decrease in crying time and stool consistency improvement, suggesting its efficacy in managing infantile colic [21,40]. Recent investigations among athletes have highlighted the strain's potential to enhance gut health, which is crucial during intense training regimens. While research suggests that DSM 17938 could improve gut microbiota health and mitigate gastrointestinal distress typically experienced by athletes, more studies are required to fully understand these effects [23,41]. Additionally, in populations with specific conditions, such as preterm infants, the strain has been linked to reduced feeding intolerance and a lower risk of necrotizing enterocolitis [25,39]. In conclusion, *L. reuteri* DSM 17938 exhibits diverse benefits, emphasizing its role as a functional probiotic across different demographic groups, including healthy individuals and those experiencing gastrointestinal disorders.

Effects of *L. reuteri* DSM 17938 on Athletic Performance

The evidence regarding the impact of *Lactobacillus reuteri* DSM 17938 on physical performance indicators, such as endurance, VO₂max, or strength, remains limited. Most investigations into this probiotic strain focus on its role in gastrointestinal health and related conditions, predominantly in infants and children, rather than athletic performance metrics. While studies have demonstrated that *L. reuteri* DSM 17938 may be effective in managing gastrointestinal issues, such as reducing constipation and diarrhea [42–44], its efficacy in enhancing physical performance parameters, like VO₂max or strength, has not been explicitly validated in the literature. The existing research primarily centers on gastrointestinal health and immune response, with some implications for overall well-being rather than targeted physical adaptations [24,45,46].

Supplementation with *Lactobacillus reuteri* DSM 17938 may positively influence biomarkers associated with oxidative stress and inflammation, which are critical factors in exercise-related adaptations. Research indicates that *L. reuteri* can suppress pro-inflammatory markers such as COX-2 in immune cells, thereby mitigating inflammation [47]. This anti-inflammatory potential can enhance recovery and adaptation to training stress, as supported by evidence of probiotics' role in maintaining immune homeostasis and regulating inflammation [48]. Additionally, *L. reuteri* has been associated with producing metabolites that regulate host immune responses, potentially countering excessive oxidative stress generated during prolonged physical activity [49].

Moreover, increased antioxidant enzyme activity has been observed with probiotic administration. A study demonstrated that probiotic strains can enhance the activities of superoxide dismutase and catalase, enzymes crucial for combating oxidative stress [50]. This enhancement could lead to improved endurance and recovery in athletes, suggesting that *L. reuteri* may aid in optimizing training adaptations through its beneficial modulation of oxidative stress and inflammatory responses [51].

Current data on the metabolic and neuromuscular benefits of *Lactobacillus reuteri* DSM 17938 in active individuals is relatively scarce, yet emerging evidence suggests potential advantages. This strain has been reported to have anti-inflammatory properties, which may indirectly support metabolic health by alleviating exercise-induced inflammation [24]. For instance, research indicates that *L. reuteri* can enhance the production of adenosine, a signaling molecule that may influence metabolic pathways beneficial for muscle recovery and energy regulation post-exercise [52].

Additionally, some studies show that probiotics like *L. reuteri* can improve gut health, which is linked to better nutrient absorption and metabolism, potentially enhancing overall athletic performance [27]. However, direct evidence of its impact on neuromuscular performance, such as strength or endurance, remains limited, and further research is required to substantiate these claims specifically in active individuals.

***L. reuteri* DSM 17938 and Recovery: Inflammation, Immunity, and Gut Health in Athletes**

Limosilactobacillus reuteri DSM 17938 is recognized for its immunomodulatory and anti-inflammatory effects, which can significantly impact post-exercise immune function and systemic inflammation. This probiotic strain facilitates immune regulation through various mechanisms, including the modulation of inflammatory cytokines like IL-6 and TNF- α , which are typically elevated after exercise [16,53]. In preclinical studies, DSM 17938 demonstrated a capacity to alleviate multi-organ inflammation in immune dysregulation models, highlighting its potential protective role in systemic inflammation following physical stress [54,55].

Moreover, the probiotic enhances gut health, which is crucial for maintaining optimal immune function post-exercise. It has been shown to support gut barrier integrity and microbiota balance, thus contributing to improved systemic inflammation levels [56,57]. By activating adenosine receptors implicated in inflammation modulation, DSM 17938 can directly influence the immune response following exercise-related stress, thereby potentially reducing unwanted inflammatory responses [55,58].

Supplementation has demonstrated potential benefits in reducing the frequency and severity of upper respiratory tract infections (URTIs) among athletes. For example, a study by Bergendiová et al. showed that pleuran (β -glucan from *Pleurotus ostreatus*) supplementation enhances cellular immune responses and can alter exercise-induced suppression of natural killer cell activity in athletes, potentially mitigating the risk of respiratory infections [59]. Similarly, probiotics, particularly *Lactobacillus* species, have been reported to improve immune responses, decreasing both the incidence and severity of infections among populations engaged in strenuous physical activity [60,61].

Moreover, regular intake of anti-inflammatory dietary supplements can modulate the immune system positively, thereby reducing systemic inflammation typically associated with intensive training [62]. Athletes experience altered immune function during heavy training, which can increase susceptibility to URTIs, highlighting the need for appropriate nutritional strategies to bolster their immune defenses [63]. Overall, evidence suggests that specific nutritional interventions can effectively support athlete immune health and minimize the impact of URTIs. *Limosilactobacillus reuteri* DSM 17938 is associated with improved gastrointestinal comfort and integrity, especially during intense physical activity.

Research indicates that this probiotic strain promotes gut health by enhancing the integrity of the intestinal barrier, which is crucial for maintaining gastrointestinal comfort under stress conditions such as heavy exercise [27,57]. The mechanism behind this involves its ability to modulate the gut microbiome, reduce gastrointestinal inflammation, and improve gut motility, thereby alleviating symptoms like bloating and discomfort commonly experienced by athletes during strenuous activities [27,64].

Furthermore, supplementation with DSM 17938 has been shown to decrease markers of inflammation within the gut and improve overall gastrointestinal function during periods of intense exercise [65]. In controlled trials, participants reported fewer gastrointestinal disturbances while taking this probiotic, suggesting its effectiveness in enhancing gut comfort and resilience during physical stress [66]. Thus, DSM 17938 serves as a valuable nutritional intervention for athletes aiming to optimize gastrointestinal integrity and comfort during intense physical exertion.

Conclusions

Limosilactobacillus reuteri DSM 17938 emerges as a promising probiotic strain with potential benefits for athletic populations, primarily through its effects on gastrointestinal health, immune modulation, and inflammation control. Although direct evidence linking this strain to measurable improvements in athletic performance metrics such as VO_2max , endurance, or strength remains limited, the indirect contributions of *L. reuteri* DSM 17938 to recovery and well-being are well-supported.

The strain's ability to enhance gut barrier integrity, reduce gastrointestinal discomfort, and modulate pro-inflammatory cytokines such as IL-6 and $\text{TNF-}\alpha$ suggests its utility in mitigating common physiological stressors faced by athletes during intense training periods. Furthermore, by supporting immune function and reducing the incidence of upper respiratory tract infections, *L. reuteri* DSM 17938 may help maintain training consistency and reduce downtime due to illness.

While most existing research has focused on pediatric and clinical populations, emerging evidence points to the strain's applicability in physically active individuals. Its role in promoting antioxidant activity, regulating inflammation, and improving gastrointestinal resilience highlights its potential as a functional component of athlete-centered nutritional strategies.

Given the growing interest in microbiome-targeted interventions in sports science, further research is warranted to assess the specific impacts of *L. reuteri* DSM 17938 on performance-related outcomes in diverse athletic settings. Randomized controlled trials with well-defined endpoints are essential to establish evidence-based recommendations for probiotic use among athletes.

In summary, although *L. reuteri* DSM 17938 is not a direct ergogenic aid, it holds significant promise as a supportive agent in athletic recovery, immune health, and gastrointestinal function—critical components of sustained high-level performance.

Disclosure

Author's contribution: conceptualization, Julia Charkot and Wojciech Bieńkowski; methodology, Wojciech Bieńkowski; software, Wojciech Bieńkowski; check, Irmina Jaszcuk, i; formal analysis, Irmina Jaszcuk; investigation, Julia Charkot; Resources, Irmina Jaszcuk; data curation, Irmina Jaszcuk; writing - rough preparation, Wojciech Bieńkowski; writing - review and editing, Julia Charkot; visualization, Wojciech Bieńkowski; Supervision, Julia Charkot; Project administration, Julia Charkot; Receiving funding, Julia Charkot

All authors have read and agreed with the published version of the manuscript.

Funding Statement:

This research received no external funding.

Institutional Review Board Statement:

Not applicable.

Informed Consent Statement:

Not applicable.

Data Availability Statement:

Not applicable.

Acknowledgments:

Not applicable.

Conflict of Interest Statement:

The authors declare no conflict of interest.

Declaration of the use of generative AI and AI-assisted technologies in the writing process.

In preparing this work, the authors used ChatGPT for the purpose of improving language and readability. After using this tool, the authors have reviewed and edited the content as needed and accept full responsibility for the substantive content of the publication.

References:

- [1] Feng W, Liu J, Cheng H, Zhang D, Tan Y, Peng C. Dietary Compounds in Modulation of Gut Microbiota-Derived Metabolites. *Frontiers in Nutrition* 2022;9. <https://doi.org/10.3389/fnut.2022.939571>.
- [2] Isiaka AB, Anakwenze VN, Uzoka UH, Ilodinso CR, Oso MO, Ekwealor CC, et al. Exploring the Role of Gut Microbiota in Human Health. *GSC Biological and Pharmaceutical Sciences* 2024;27:051–9. <https://doi.org/10.30574/gscbps.2024.27.1.0100>.

- [3] Zhang L, Liu Y, Xinzhou W, Zhang X. Physical Exercise and Diet: Regulation of Gut Microbiota to Prevent and Treat Metabolic Disorders to Maintain Health. *Nutrients* 2023;15:1539. <https://doi.org/10.3390/nu15061539>.
- [4] Marano G, Traversi G, Gaetani E, Gasbarrini A, Mazza M. Gut Microbiota in Women: The Secret of Psychological and Physical Well-Being. *World Journal of Gastroenterology* 2023;29:5945–52. <https://doi.org/10.3748/wjg.v29.i45.5945>.
- [5] Yoo JY, McSkimming D, Rajan K, Sarkar A, Labbé N, Groër M, et al. A Preliminary Study Exploring the Relationship Between Occupational Health Hazards and Gut Microbiota Among Firefighters. *Life* 2023;13:1928. <https://doi.org/10.3390/life13091928>.
- [6] Menezes DB, Bello FD, Brito CJ, Couto C, Ciro J, Miarka B. *Journal of Physical Education and Sport* 2019;2019. <https://doi.org/10.7752/jpes.2019.01086>.
- [7] Hashimoto K. Gut–microbiota–brain Axis by Bile Acids in Depression. *Psychiatry and Clinical Neurosciences* 2022;76:281–281. <https://doi.org/10.1111/pcn.13370>.
- [8] Zhou P, Chen C, Patil S, Dong S. Unveiling the Therapeutic Symphony of Probiotics, Prebiotics, and Postbiotics in Gut-Immune Harmony. *Frontiers in Nutrition* 2024;11. <https://doi.org/10.3389/fnut.2024.1355542>.
- [9] Nami Y, Barghi A, Shahgolzari M, Salehian MH, Haghshenas B. Mechanism of Action and Beneficial Effects of Probiotics in Amateur and Professional Athletes. *Food Science & Nutrition* 2024;13. <https://doi.org/10.1002/fsn3.4658>.
- [10] Smarkusz-Zarzecka J, Ostrowska L, Leszczyńska J, Cwalina U. Effect of a Multi-Strain Probiotic Supplement on Gastrointestinal Symptoms and Serum Biochemical Parameters of Long-Distance Runners: A Randomized Controlled Trial. *International Journal of Environmental Research and Public Health* 2022;19:9363. <https://doi.org/10.3390/ijerph19159363>.
- [11] Díaz-Jiménez J, Sánchez-Sánchez E, Ordóñez FJ, Rosety I, Díaz AJ, Rosety-Rodríguez M, et al. Impact of Probiotics on the Performance of Endurance Athletes: A Systematic Review. *International Journal of Environmental Research and Public Health* 2021;18:11576. <https://doi.org/10.3390/ijerph182111576>.
- [12] Przewłócka K, Folwarski M, Kaczmarczyk M, Skonieczna-Żydecka K, Palma J, Bytowska ZK, et al. Combined Probiotics With Vitamin D3 Supplementation Improved Aerobic Performance and Gut Microbiome Composition in Mixed Martial Arts Athletes. *Frontiers in Nutrition* 2023;10. <https://doi.org/10.3389/fnut.2023.1256226>.
- [13] Jäger R, Mohr AE, Carpenter KC, Kerksick CM, Purpura M, Moussa A, et al. International Society of Sports Nutrition Position Stand: Probiotics. *Journal of the International Society of Sports Nutrition* 2019;16. <https://doi.org/10.1186/s12970-019-0329-0>.
- [14] Sagheddu V, Uggeri F, Belogi L, Remollino L, Brun P, Bernabè G, et al. The Biotherapeutic Potential of *Lactobacillus Reuteri* Characterized Using a Target-Specific Selection Process. *Frontiers in Microbiology* 2020;11. <https://doi.org/10.3389/fmicb.2020.00532>.

- [15] Rosander A, Connolly E, Roos S. Removal of Antibiotic Resistance Gene-Carrying Plasmids From *Lactobacillus Reuteri* ATCC 55730 and Characterization of the Resulting Daughter Strain, L . *reuteri* DSM 17938. *Applied and Environmental Microbiology* 2008;74:6032–40. <https://doi.org/10.1128/aem.00991-08>.
- [16] Hoang TK, He B, Wang T, Tran DQ, Rhoads JM, Liu Y. Protective Effect of *Lactobacillus Reuteri* DSM 17938 Against Experimental Necrotizing Enterocolitis Is Mediated by Toll-Like Receptor 2. *Ajp Gastrointestinal and Liver Physiology* 2018;315:G231–40. <https://doi.org/10.1152/ajpgi.00084.2017>.
- [17] Spreckels JE, Wejryd E, Marchini G, Jónsson B, Vries DH d., Jenmalm MC, et al. *Lactobacillus Reuteri* Colonisation of Extremely Preterm Infants in a Randomised Placebo-Controlled Trial. *Microorganisms* 2021;9:915. <https://doi.org/10.3390/microorganisms9050915>.
- [18] Dommels YE, Kemperman R, Yvonne E. M. P. Zebregs, Draaisma RB, Jol A, Wolvers D, et al. Survival Of *Lactobacillus Reuteri* DSM 17938 And *Lactobacillus Rhamnosus* GG in the Human Gastrointestinal Tract With Daily Consumption of a Low-Fat Probiotic Spread. *Applied and Environmental Microbiology* 2009;75:6198–204. <https://doi.org/10.1128/aem.01054-09>.
- [19] Șufaru I-G, Lazăr L, Șincar D-C, Mârțu M-A, Păsărin L, Luca ED, et al. Clinical Effects of Locally Delivered *Lactobacillus Reuteri* as Adjunctive Therapy in Patients With Periodontitis: A Split-Mouth Study. *Applied Sciences* 2022;12:2470. <https://doi.org/10.3390/app12052470>.
- [20] Vaz SR, Tofoli MHC, Avelino MAG, Costa PS. Probiotics for Infantile Colic: Is There Evidence Beyond Doubt? A Meta-analysis and Systematic Review. *Acta Paediatrica* 2023;113:170–82. <https://doi.org/10.1111/apa.17036>.
- [21] Xu M, Wang J, Wang N, Sun F, Wang L, Liu X. The Efficacy and Safety of the Probiotic Bacterium *Lactobacillus Reuteri* DSM 17938 for Infantile Colic: A Meta-Analysis of Randomized Controlled Trials. *Plos One* 2015;10:e0141445. <https://doi.org/10.1371/journal.pone.0141445>.
- [22] Jadrešin O, Hojsak I, Mišak Z, Kekez AJ, Trbojević T, Ivković L, et al. *Lactobacillus Reuteri* DSM 17938 in the Treatment of Functional Abdominal Pain in Children. *Journal of Pediatric Gastroenterology and Nutrition* 2017;64:925–9. <https://doi.org/10.1097/mpg.0000000000001478>.
- [23] Srinivasan RS, Kesavelu D, Veligandla KC, Muni SK, Mehta S. *Lactobacillus Reuteri* DSM 17938: Review of Evidence in Functional Gastrointestinal Disorders. *Pediatrics & Therapeutics* 2018;08. <https://doi.org/10.4172/2161-0665.1000350>.
- [24] Janson TM, Ramenzoni LL, Hatz CR, Schlagenhauf U, Attin T, Schmidlin PR. *Limosilactobacillus Reuteri* Supernatant Attenuates Inflammatory Responses of Human Gingival Fibroblasts to LPS but Not to Elevated Glucose Levels. *Journal of Periodontal Research* 2024;59:974–81. <https://doi.org/10.1111/jre.13290>.

- [25] Hunter C, Dimaguila MAV, Gál P, Wimmer J, Ransom JL, Carlos RQ, et al. Effect of Routine Probiotic, *Lactobacillus Reuteri* DSM 17938, Use on Rates of Necrotizing Enterocolitis in Neonates With Birthweight < 1000 Grams: A Sequential Analysis. *BMC Pediatrics* 2012;12. <https://doi.org/10.1186/1471-2431-12-142>.
- [26] Захарова ИИ, Berezhnaya IV, Кучина АЕ, Дедикова ОВ. Probiotic *Lactobacillus Reuteri* DSM 17938: What Is Known About It Today? *Meditsinskiy Sovet = Medical Council* 2019;236–42. <https://doi.org/10.21518/2079-701x-2019-17-236-242>.
- [27] Abuqwider J, Porzio AD, Barrella V, Gatto C, Sequino G, Filippis FD, et al. *Limosilactobacillus Reuteri* DSM 17938 Reverses Gut Metabolic Dysfunction Induced by Western Diet in Adult Rats. *Frontiers in Nutrition* 2023;10. <https://doi.org/10.3389/fnut.2023.1236417>.
- [28] Ichsan B, Lestari N, Sulistyani. *Lactobacillus Reuteri* DSM 17938 in Infantile Colic: A Systematic Review and Meta-Analysis. *Bioscientia Medicina Journal of Biomedicine and Translational Research* 2022;6:1446–54. <https://doi.org/10.37275/bsm.v6i3.457>.
- [29] Brenner LA, Forster JE, Stearns-Yoder KA, Stamper CE, Hoisington AJ, Brostow DP, et al. Evaluation of an Immunomodulatory Probiotic Intervention for Veterans With Co-Occurring Mild Traumatic Brain Injury and Posttraumatic Stress Disorder: A Pilot Study. *Frontiers in Neurology* 2020;11. <https://doi.org/10.3389/fneur.2020.01015>.
- [30] Urbańska M, Szajewska H. The Efficacy of *Lactobacillus Reuteri* DSM 17938 in Infants and Children: A Review of the Current Evidence. *European Journal of Pediatrics* 2014;173:1327–37. <https://doi.org/10.1007/s00431-014-2328-0>.
- [31] He B, Hoang TK, Tran DQ, Rhoads JM, Liu Y. Adenosine A2A Receptor Deletion Blocks the Beneficial Effects of *Lactobacillus Reuteri* in Regulatory T-Deficient Scurfy Mice. *Frontiers in Immunology* 2017;8. <https://doi.org/10.3389/fimmu.2017.01680>.
- [32] Indrio F, Riezzo G, Tafuri S, Ficarella M, Carlucci B, Bisceglia M, et al. Probiotic Supplementation in Preterm: Feeding Intolerance and Hospital Cost. *Nutrients* 2017;9:965. <https://doi.org/10.3390/nu9090965>.
- [33] Patro-Gołąb B, Szajewska H. Systematic Review With Meta-Analysis: *Lactobacillus Reuteri* DSM 17938 for Treating Acute Gastroenteritis in Children. An Update. *Nutrients* 2019;11:2762. <https://doi.org/10.3390/nu11112762>.
- [34] Maragkoudaki M, Chouliaras G, Moutafi AC, Thomas A, Orfanakou A, Papadopoulou A. Efficacy of an Oral Rehydration Solution Enriched With *Lactobacillus Reuteri* DSM 17938 and Zinc in the Management of Acute Diarrhoea in Infants: A Randomized, Double-Blind, Placebo-Controlled Trial. *Nutrients* 2018;10:1189. <https://doi.org/10.3390/nu10091189>.
- [35] Kubota M, Ito K, Tomimoto K, Kanazaki M, Tsukiyama K, Kubota A, et al. *Lactobacillus Reuteri* DSM 17938 and Magnesium Oxide in Children With Functional Chronic Constipation: A Double-Blind and Randomized Clinical Trial. *Nutrients* 2020;12:225. <https://doi.org/10.3390/nu12010225>.

- [36] Contreras AG, Vásquez-Garibay EM, Sánchez-Ramírez CA, Fafutis-Morris M, Rizo VD. Lactobacillus Reuteri DSM 17938 and Agave Inulin in Children With Cerebral Palsy and Chronic Constipation: A Double-Blind Randomized Placebo Controlled Clinical Trial. *Nutrients* 2020;12:2971. <https://doi.org/10.3390/nu12102971>.
- [37] Dinleyici EÇ, Dalgıç N, Güven Ş, Akcan ÖM, Yasa O, Kurugöl Z, et al. Lactobacillus Reuteri DSM 17938 Shortens Acute Infectious Diarrhea in a Pediatric Outpatient Setting. *Jornal De Pediatria* 2015;91:392–6. <https://doi.org/10.1016/j.jped.2014.10.009>.
- [38] Indrio F, Riezzo G, Raimondi F, Bisceglia M, Filannino A, Cavallo L, et al. Lactobacillus Reuteri Accelerates Gastric Emptying and Improves Regurgitation in Infants. *European Journal of Clinical Investigation* 2010;41:417–22. <https://doi.org/10.1111/j.1365-2362.2010.02425.x>.
- [39] Kaban RK, Wardhana, Hegar B, Rohsiswatmo R, Handryastuti S, Amelia N, et al. Lactobacillus Reuteri DSM 17938 Improves Feeding Intolerance in Preterm Infants. *Pediatric Gastroenterology Hepatology & Nutrition* 2019;22:545. <https://doi.org/10.5223/pghn.2019.22.6.545>.
- [40] Dryl R, Szajewska H. Probiotics for Management of Infantile Colic: A Systematic Review of Randomized Controlled Trials. *Archives of Medical Science* 2018;14:1137–43. <https://doi.org/10.5114/aoms.2017.66055>.
- [41] Khmaladze I, Butler EI, Fabre S, Gillbro JM. Lactobacillus Reuteri DSM 17938—A Comparative Study on the Effect of Probiotics and Lysates on Human Skin. *Experimental Dermatology* 2019;28:822–8. <https://doi.org/10.1111/exd.13950>.
- [42] Wu X. Effectiveness of a Probiotic for Functional Chronic Constipation: A Meta-Analysis of Randomized Controlled Trials. *Iranian Journal of Pediatrics* 2020;30. <https://doi.org/10.5812/ijp.102212>.
- [43] Saviano A, Brigida M, Migneco A, Gayani G, Zanza C, Candelli M, et al. Lactobacillus Reuteri DSM 17938 (*Limosilactobacillus Reuteri*) in Diarrhea and Constipation: Two Sides of the Same Coin? *Medicina* 2021;57:643. <https://doi.org/10.3390/medicina57070643>.
- [44] Pärty A, Rautava S, Kalliomäki M. Probiotics on Pediatric Functional Gastrointestinal Disorders. *Nutrients* 2018;10:1836. <https://doi.org/10.3390/nu10121836>.
- [45] Kim H, Cho J-W, Kim D-H, Kang W-J. Effects of Lactobacillus Reuteri Intake on the Periodontal Pathogens. *International Journal of Clinical Preventive Dentistry* 2024;20:12–8. <https://doi.org/10.15236/ijcpd.2024.20.1.12>.
- [46] Mobini R, Tremaroli V, Ståhlman M, Karlsson F, Levin M, Ljungberg M, et al. Metabolic Effects of Lactobacillus Reuteri DSM 17938 in People With Type 2 Diabetes: A Randomized Controlled Trial. *Diabetes Obesity and Metabolism* 2017;19:579–89. <https://doi.org/10.1111/dom.12861>.
- [47] Jang A, Rod-in W, Monmai C, Sohn M, Kim T, Jeon M-G, et al. Anti-Inflammatory Potential of Lactobacillus Reuteri LM1071 via Eicosanoid Regulation in LPS-stimulated RAW264.7 Cells. *Journal of Applied Microbiology* 2022;133:67–75. <https://doi.org/10.1111/jam.15331>.

- [48] Hu R, Lin H, Wang M, Zhao Y, Liu H, Min Y, et al. Lactobacillus Reuteri-Derived Extracellular Vesicles Maintain Intestinal Immune Homeostasis Against Lipopolysaccharide-Induced Inflammatory Responses in broilers. *Journal of Animal Science and Biotechnology* 2021;12. <https://doi.org/10.1186/s40104-020-00532-4>.
- [49] Watthanasakphuban N, Srila P, Pinmanee P, Sompinit K, Rattanaorn K, Peterbauer CK. Development of High Cell Density Limosilactobacillus Reuteri KUB-AC5 for Cell Factory Using Oxidative Stress Reduction Approach. *Microbial Cell Factories* 2023;22. <https://doi.org/10.1186/s12934-023-02076-4>.
- [50] Rienzi SCD, Danhof HA, Forshee MD, Roberts A, Britton RA. Limosilactobacillus Reuteri Promotes the Expression and Secretion of Enteroendocrine- and Enterocyte-derived Hormones. *The FASEB Journal* 2025;39. <https://doi.org/10.1096/fj.202401669r>.
- [51] Tang Q, Yi H, Hong W, Wu Q, Yang X, Hu S, et al. Comparative Effects of L. Plantarum CGMCC 1258 and L. Reuteri LR1 on Growth Performance, Antioxidant Function, and Intestinal Immunity in Weaned Pigs. *Frontiers in Veterinary Science* 2021;8. <https://doi.org/10.3389/fvets.2021.728849>.
- [52] Lundberg L, Mishra PP, Liu P, Forsberg MM, Sverremark-Ekström E, Grompone G, et al. Bifidobacterium Longum Subsp. longum BG-L47 Boosts Growth and Activity Of Limosilactobacillus Reuteri DSM 17938 and Its Extracellular Membrane Vesicles. *Applied and Environmental Microbiology* 2024;90. <https://doi.org/10.1128/aem.00247-24>.
- [53] Liu Y, Armbrister SA, Okeugo B, Mills T, Daniel RC, Oh J, et al. Probiotic-Derived Ecto-5'-Nucleotidase Produces Anti-Inflammatory Adenosine Metabolites in Treg-Deficient Scurfy Mice 2023. <https://doi.org/10.21203/rs.3.rs-2781715/v1>.
- [54] Kostandy EN, Suh JH, Tian X, Okeugo B, Rubin E, Shirai S, et al. Probiotic Limosilactobacillus Reuteri DSM 17938 Changes Foxp3 Deficiency-Induced Dyslipidemia and Chronic Hepatitis in Mice. *Nutrients* 2024;16:511. <https://doi.org/10.3390/nu16040511>.
- [55] Liu Y, He B, Hoang TK, Tran DQ, Rhoads JM. Deletion of Adenosine A2A Receptor Blocks the Beneficial Effects of Lactobacillus Reuteri on Treg-Deficiency-Induced Autoimmunity. *The Journal of Immunology* 2018;200:176.21-176.21. <https://doi.org/10.4049/jimmunol.200.suppl.176.21>.
- [56] Lai Z, Gong F. Protective Effects of Lactobacillus Reuteri on Intestinal Barrier Function in a Mouse Model of Neonatal Necrotizing Enterocolitis. *American Journal of Perinatology* 2022;41:e386–93. <https://doi.org/10.1055/s-0042-1755554>.
- [57] Dargenio VN, Cristofori F, Dargenio C, Giordano P, Indrio F, Celano G, et al. Use of Limosilactobacillus Reuteri DSM 17938 in Paediatric Gastrointestinal Disorders: An Updated Review. *Beneficial Microbes* 2022;13:221–42. <https://doi.org/10.3920/bm2021.0151>.
- [58] Liu Y, He B, Hoang TK, Wang T, Taylor CM, Tian X, et al. Therapeutic Effect of Lactobacillus Reuteri DSM 17938 on Treg-Deficiency-Induced Autoimmunity (IPEX Syndrome) via the Inosine-Adenosine 2A Receptors. *The Journal of Immunology* 2017;198:127.22-127.22. <https://doi.org/10.4049/jimmunol.198.suppl.127.22>.

- [59] Bergendiová K, Tibenská E, Majtán J. Pleuran (B-Glucan From *Pleurotus Ostreatus*) Supplementation, Cellular Immune Response and Respiratory Tract Infections in Athletes. *European Journal of Applied Physiology* 2011;111:2033–40. <https://doi.org/10.1007/s00421-011-1837-z>.
- [60] Noorifard M, Ebrahimi E, Moghaddam AD, Asemi Z, Farahani RH, Jazayeri SMM. Effects of Probiotic Supplementation on Immune Response in Soldiers: A Randomized, Double-Blinded, Placebo-Controlled Trial. *Annals of Military and Health Sciences Research* 2020;18. <https://doi.org/10.5812/amh.100540>.
- [61] Walsh NP. Nutrition and Athlete Immune Health: New Perspectives on an Old Paradigm. *Sports Medicine* 2019;49:153–68. <https://doi.org/10.1007/s40279-019-01160-3>.
- [62] Buonocore D, Negro M, Arcelli E, Marzatico F. Anti-Inflammatory Dietary Interventions and Supplements to Improve Performance During Athletic Training. *Journal of the American College of Nutrition* 2015;34:62–7. <https://doi.org/10.1080/07315724.2015.1080548>.
- [63] Kim J. Nutritional Supplement for Athletic Performance: Based on Australian Institute of Sport Sports Supplement Framework. *Exercise Science* 2019;28:211–20. <https://doi.org/10.15857/ksep.2019.28.3.211>.
- [64] Riezzo G, Orlando A, D’Attoma B, Linsalata M, Martulli M, Russo F. Randomised Double Blind Placebo Controlled Trial on *Lactobacillus Reuteri* DSM 17938: Improvement in Symptoms and Bowel Habit in Functional Constipation. *Beneficial Microbes* 2018;9:51–60. <https://doi.org/10.3920/bm2017.0049>.
- [65] Riezzo G, Chimienti G, Orlando A, D’Attoma B, Clemente C, Russo F. Effects of Long-Term Administration of *Lactobacillus Reuteri* DSM-17938 on Circulating Levels of 5-Ht and BDNF in Adults With Functional Constipation. *Beneficial Microbes* 2019;10:137–48. <https://doi.org/10.3920/bm2018.0050>.
- [66] Liu Y, Fatheree NY, Mangalat N, Rhoads JM. *Lactobacillus Reuteri* strains Reduce Incidence and Severity of Experimental Necrotizing Enterocolitis via Modulation of TLR4 and NF- κ B Signaling in the Intestine. *Ajp Gastrointestinal and Liver Physiology* 2012;302:G608–17. <https://doi.org/10.1152/ajpgi.00266.2011>.